Janux Therapeutics (JANX) Receivables - Other (2023 - 2025)
Janux Therapeutics (JANX) has disclosed Receivables - Other for 3 consecutive years, with $6.4 million as the latest value for Q4 2025.
- Quarterly Receivables - Other rose 19.46% to $6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.4 million through Dec 2025, up 19.46% year-over-year, with the annual reading at $6.4 million for FY2025, 19.46% up from the prior year.
- Receivables - Other for Q4 2025 was $6.4 million at Janux Therapeutics, up from $6.3 million in the prior quarter.
- The five-year high for Receivables - Other was $6.4 million in Q4 2025, with the low at $2.2 million in Q4 2023.
- Average Receivables - Other over 3 years is $4.9 million, with a median of $5.4 million recorded in 2024.
- The sharpest move saw Receivables - Other soared 149.01% in 2024, then increased 19.46% in 2025.
- Over 3 years, Receivables - Other stood at $2.2 million in 2023, then skyrocketed by 149.01% to $5.4 million in 2024, then grew by 19.46% to $6.4 million in 2025.
- According to Business Quant data, Receivables - Other over the past three periods came in at $6.4 million, $6.3 million, and $5.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.